Professor and Head Division of Radiation Oncology Stellenbosch University and Tygerberg Hospital Cape Town South Africa
|
|
- Elfreda Bond
- 5 years ago
- Views:
Transcription
1 STAGE III NONSMALL CELL LUNG CANCER TREATMENT APPROACHES WE LIKE TO PRACTICE... ALMOST UNETHICALLY Branislav Jeremic, MD, PhD Professor and Head Division of Radiation Oncology Stellenbosch University and Tygerberg Hospital Cape Town South Africa 1
2 CONFLICT OF INTEREST NONE TO DECLARE 2
3 CONCURRENT RADIOCHEMOTHERAPY STANDARD TREATMENT IN LOCALLY ADVANCED, INOPERABLE (STAGE III) NSCLC Cochrane Database Systematic Review O Rourke et al, 2010 Chinese Meta-Analysis Liang et al, Int J Cancer, 2010 IGR/MRC IPD meta-analysis Auperin et al, JCO, 2010
4 CONCURRENT RADIOCHEMOTHERAPY IN LOCALLY ADVANCED (STAGE III) NSCLC EXISTING ROOM FOR AN IMPROVEMENT INTENSIFICATION OF TREATMENT IMPROVED OUTCOMES? INCREASED TOXICITY?
5 RTOG 0617/NCCTG N0628/CALGB R A N D O M I Z E RT: 60 Gy Paclitaxel Carboplatin +/- Cetuximab RT: 74 Gy Paclitaxel Carboplatin +/- Cetuximab Paclitaxel Carboplatin X 2 +/- Cetuximab
6 Overall Survival (%) Gy arm: 81% Gy arm: 70% 25 0 HR=1.45 (1.02, 2.05) p*= Patients at Risk Months since Randomization 60 Gy Gy *One-sided p-value, left tail 60 Gy 74 Gy Dead Total The higher dose arm fared worse!
7 What s THE reason that dose escalation is negative? 1) Dose Threshold? 5) Type of failure? 2) Toxicity? 6) Result is actually TRUE? 3) Table of Characteristics? 7) Totally novel strategies? 4) Technical factors?
8 RTOG 0617 Definitely, Probably, or Possibly Related to Treatment (using CTCAE Version 3.0) September 2011 Arm A: 60 Gy +/- Cetuximab (n=192) Grade Arm B: 74 Gy +/- Cetuximab (n=183) Grade Worst non-hematologic 79 (41.1%) 14 (7.3%) 4 (2.1%) 85 (46.4%) 17 (9.3%) 8 (4.4%) Worst overall 84 (43.8%) 45 (23.4%) 4 (2.1%) 78 (42.6%) 52 (28.4%) 8 (4.4%) Grade 5 Events (n=4) (n=8) -As scored by institution -No significant difference 2 Pulmonary 1 Thrombosis 1 Death NOS 2 Pulmonary 1 Thrombosis 1 Upper GI Hemorrhage 1 Pulmonary Hemorrhage 1 Pneumonia NOS 1 Esophageal 1 Death NOS
9 LOCALLY ADVANCED NSCLC ACUTE HIGH-GRADE (> 3) ESOPHAGITIS Study/author RT (Gy) CHT Sequence Esophagitis RTOG (QD) - - < 5% RTOG (QD) PV induction < 5% RTOG (QD) PE induction 6% RTOG (BID) PV concurrent 24% RTOG (BID) PE concurrent 53% RTOG (BID) PE concurrent 36% LUN (QD) T concurrent 17% LUN (QD) TC concurrent 25% LUN (BID) TC concurrent 26% Jeremic et al 69.6 (BID) CE concurrent 10-15% Jeremic et al 67.6 (BID) TC concurrent 17%
10 CONCURRENT RADIOCHEMOTHERAPY LOCALLY ADVANCED (STAGE III) NSCLC Low-dose daily CHT leads to low toxicity Jeremic et al, 1996; 2001; 2005 Koning CC et al, 2013 Hfx RT offers better LC and OS Jeremic et al, 1995; 1996; 1998; 2001; 2005 Mauguen et al, 2012
11 CONCURRENT RADIOCHEMOTHERAPY LOCALLY ADVANCED (STAGE III) NSCLC Studies included Stage IIIA and pn2 patients Lower burden (T and/or N) of tumour cells More aggressive approach justified? Better outcome with intensification? Concurrent radiochemo still a standard!
12 CONCURRENT RADIOCHEMOTHERAPY LOCALLY ADVANCED (STAGE III) NSCLC DO WE ALWAYS PRACTICE IT? OTHER APPROACHES? EVIDENCE?
13 CONCURRENT RADIOCHEMOTHERAPY LOCALLY ADVANCED (STAGE III) NSCLC DO WE ALWAYS PRACTICE IT? NO! OTHER APPROACHES? MANY! EVIDENCE? NONE! OTHER APPROACHES STILL ADVOCATED WIDELY!! (NCCN, NICE, SIGN, ESTRO, ESMO, CIA, KGB, MI6 you name it)
14 LOCALLY ADVANCED (STAGE III) NSCLC TWO MOST TROUBLESOME SITUATIONS SURGERY IN STAGE IIIA/pN2 NSCLC CONSOLIDSATION CHEMO IN STAGE III
15 STAGE IIIA NSCLC Low disease volume Greater chances for cure? More aggressive treatment justified? Surgery and/or CHT and/or RT
16 STAGE IIIA NSCLC (prospective studies) Author Phase Stage N Treatment MST (mos) Shepherd III IIIA (N2) Johnstone III IIIA Van Meerbeeck III III (N2) RT CHT+S CHT+S CHT/RT CHT+S CHT/RT Albain III IIIA 429 CHT/RT+S CHT/RT Thomas III IIIA/B CHT+RT (bid)/cht+s CHT+S+PORT (qd) OS (%) n.r. 0% 70 (1yr) 66 (1yr) 15.7 (5yr) 14 (5yr) 27.2 (5yr) 20.3 (5yr) 21 (5yr) 18 (5yr) Mortality (%) 7% 3% 9% <1% 8% 2% 9% 5% Gottfried III IIB (T3N0) IIIA/B (T4N0) CHT+S CHT+S+CHT (3yr) 49 (3yr) 3% Sorenson III T1-3N2M0 (pn2) CHT + S + RT CHT + RT (5yr) 16 (5yr) n.r.
17 STAGE IIIA NSCLC (prospective studies) Author Phase Stage N Treatment MST (mos) Shepherd III IIIA (N2) Johnstone III IIIA Van Meerbeeck III III (N2) RT CHT+S CHT+S CHT/RT CHT+S CHT/RT Albain III IIIA 429 CHT/RT+S CHT/RT Thomas III IIIA/B CHT+RT (bid)/cht+s CHT+S+PORT (qd) OS (%) n.r. 0% 70 (1yr) 66 (1yr) 15.7 (5yr) 14 (5yr) 27.2 (5yr) 20.3 (5yr) 21 (5yr) 18 (5yr) Mortality (%) 7% 3% 9% <1% 8% 2% 9% 5% Gottfried III IIB (T3N0) IIIA/B (T4N0) CHT+S CHT+S+CHT (3yr) 49 (3yr) 3% Sorenson III T1-3N2M0 (pn2) CHT + S + RT CHT + RT (5yr) 16 (5yr) n.r.
18 STAGE IIIA NSCLC (retrospective studies) Author Phase Stage N Treatment MST (mos) OS (%) Mortality (%) Uy retrospective IIIA (N2) 40 CHT/RT+S+CHT (3yr) 7% Yap retrospective IIIA/B 33 CHT/RT+S (2 yr) <1% Taylor retrospective ciiia 107 CHT +S (+ PORT) RT-CHT (5yr) 30 (5yr) n.r. Mac Manus retrospective IIIA 25 RT-CHT (4yr) n.r. Seder retrospective IIIA CHT/RT + S RT-CHT n.r. n.r. 2% 2% Jeremic retrospective ciiia 222 RT-CHT (5yr) 0
19 STAGE IIIA NSCLC (retrospective studies) Author Phase Stage N Treatment MST (mos) OS (%) Mortality (%) Uy retrospective IIIA (N2) 40 CHT/RT+S+CHT (3yr) 7% Yap retrospective IIIA/B 33 CHT/RT+S (2 yr) <1% Taylor retrospective ciiia 107 CHT +S (+ PORT) RT-CHT (5yr) 30 (5yr) n.r. Mac Manus retrospective IIIA 25 RT-CHT (4yr) n.r. Seder retrospective IIIA CHT/RT + S RT-CHT n.r. n.r. 2% 2% Jeremic retrospective ciiia 222 RT-CHT (5yr) 0
20 STAGE IIIA NSCLC Author Study/ phase Stage N Treatment MST (mos) OS (%) Mortality (%) Remarks Shepherd III IIIA (N2) RT CHT+S n.r. 0% Johnstone III IIIA CHT+S CHT/RT (1yr) 66 (1yr) 7% 3% bulky N2 in 54% pts Van Meerbeeck III III (N2) CHT+S** CHT/RT (5yr) 14 (5yr) 9% <1% ** PORT in 40% pts Albain III IIIA 429 CHT/RT+S CHT/RT (5yr) 20.3 (5yr) 8% 2% 26% mortality in 54 patients undergoing pneumonectomy Thomas III IIIA/B CHT+RT (bid)/cht+s CHT+S+PORT (qd) (5yr) 18 (5yr) 9% 5% Gottfried III IIB (T3N0) IIIA/B (T4N0) CHT+S CHT+S+CHT (3yr) 49 (3yr) 3% Sorenson III T1-3N2M0 (pn2) CHT + S + RT CHT + RT (5yr) 16 (5yr) n.r. Uy retrospective IIIA (N2) 40 CHT/RT+S+CHT (3yr) 7% Yap retrospective IIIA/B 33 CHT/RT+S (2 yr) <1% Taylor retrospective ciiia 107 CHT +S (+ PORT) RT-CHT (5yr) 30 (5yr) n.r. KPS < 70 in 2% pts W. loss > 5% in 10% pts Jeremic retrospective ciiia 177 RT-CHT (5yr) 0 All pts had KPS and weight loss < 5%
21 STAGE IIIA NSCLC NO EVIDENCE FOR ROLE OF SURGERY EVIDENCE ABOUT TOXICITY/MORTALITY MYRIAD OF POTENTIAL PROGNOSTICATORS A LOT OF PATIENTS STILL BLEED (volunteer needed to inform NCCN, ESTRO, ESMO, CIA, KGB, MI6..)
22 SELECTED CONSOLIDATION CHEMOTHERAPY STUDIES IN LOCALLY ADVANCED NSCLC Study Year Concurrent RT-CHT Consolidation CHT MST (months) Survival Lau et al 2001 RT/TC TC x % (2 yr) Ratanatharathorn et al 2001 RT/TC TC x % ( 1 yr) Albain et al 2002 RT/PE PE x % (5 yr) Gandara et al 2003 RT/PE D x % (5 yr) Park et al 2003 RT/PoE PoE x % (5 yr) Sakai et al 2004 RT/DC DC x % (2 yr) Sekine et al 2006 RT/PV D x % (3 yr) Iwasaki et al 2006 RT/PD PD X % (2 yr) Jain et al 2009 RT/DC DC x % (2 yr) Ohyanagi et al 2009 RT/PS-1 PS-1 x % (2 yr) Oshita et al 2010 RT/NI NI x % (5 yr) Bastos et al 2010 RT/IrC D x % (3 yr) 22 Ramalingam et a 2013 RT/Cet CetTC/weekly 19 64% (1 yr)
23 CONSOLIDATION CHT STUDIES PROMISING RESULTS ACCEPTABLE TOXICITY (?) FURTHER VERIFICATION (PHASE III) (?)
24 CONSOLIDATION CHT STUDIES PROBLEM (I) LACK OF DOCUMENTED PATTERN OF FAILURE IN CR/ PR AFTER CONCURRENT RT/CHT
25 CONSOLIDATION CHT STUDIES PROBLEM (II) UNEXPLAINED WHERE CONSOLIDATION CHT IS ACTING
26 CONSOLIDATION CHT STUDIES PROBLEM (III) SAME/DIFFERENT DRUGS MAY HAVE EXERTED DIFFERENT ACTIVITY ON LOCORGIONAL AND/OR DISTANT LEVEL
27 CONSOLIDATION CHT STUDIES PROBLEM (IV) SOME PATIENTS (SD) MAY HAVE UNNECESSARILY BEEN EXPOSED TO TOXIC TREATMENT
28 RANDOMIZED STUDIES ON CONSOLIDATION THERAPY IN LOCALLY ADVANCED NSCLC STUDY YEAR CONCURRENT RT-CHT CONSOLDIATION CHT MST (months) OS Hanna et al 2008 RT/PE no % (3yrs) RT/PE DOC x % (3yrs) Kelly et al 2008 RT/PE DOC x % (2 yrs) RT/PE DOC x 3 + Gefitinib 23 46% (2yrs) Hoang et al 2012 RT/TC Pre-RT : PC x % (3yrs) RT/TC Pre-RT : PC x 2 Post-RT : Thalidomide 16 23% (3yrs) 28
29 CONCURRENT RT-CHT +/- CONSOLIDATION CHT Tsujino et al, JTO, 2013 ENDPOINT CCT+ CCT- SIGNIFICANCE No. studies No. pts Pooled 3yr 27% 24.8% Pooled MST 19 (months) (95% CI, ) 17.9 (months) (95% CI, ) Predicted HR 0.94 (95% CI, ) P = 0.40 Grade 3-5 toxicity 29 pneumonitis esophagitis neutropenia leukopenia deaths n.s. n.s. n.s. n.s. n.s.
30 CONCURRENT RT-CHT and CONSOLIDATION THERAPY DATA FROM RANDOMZIED TRIALS DIFFER MORE TOXICIITY IN CONSOLIDATION ARMS POORER QUALITY OF LIFE IN CONSOLIDATION ARMS TOXIC DEATHS 2-6% IN CONSOLIDATION ARMS 30
31 FOR THOSE WHO MAY WISH TO TEST IT FURTHER
32 CONSOLIDATION CHT SAME STORY AS WITH SURGERY NO EVIDENCE AT ALL PATIENTS STILL SERIOUSLY POISONED ANOTHER VOLUNTEER NEEDED
33 CONCLUSION (I) EBO CLEAR WITH FACTS AND FIGURES CONCURRENT RT-CHT STANDARD IN ALL STAGE III NSCLC LESS MORTALITY AND HIGH-GRADE TOXICITY THERAPEUTIC BENEFIT CLEARLY FAVOURS IT!
34 CONCLUSION (II) MANY PEOPLE AND ORG/INC/LTD ALMOST.. UNETHICALLY (?) TREAT PATIENTS DO WE NEED AN ORCHESTRATED ACTION?
35 Cape Point
36 A view from Chapman s peak Gracias!
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationMeta-analysis : clinician s point of view
Meta-analysis : clinician s point of view Prof. Branislav Jeremic, MD, PhD Head, Division of Radiation Oncology Stellenbosch University /Tygerberg Hospital Cape Town South Africa CONFLICT OF INTEREST NONE
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationDisclosures. Preoperative Treatment: Chemotherapy or ChemoRT? Adjuvant chemotherapy helps. so what about chemo first?
Disclosures Preoperative Treatment: Chemotherapy or ChemoRT? Advisory boards Genentech (travel only), Pfizer Salary support for clinical trials Celgene, Merck, Merrimack Matthew Gubens, MD, MS Assistant
More informationThe Role of Surgery in the Management of Stage 3A Lung Cancer. Zane Hammoud, M.D. Chief, General Thoracic Surgery Henry Ford Hospital
The Role of Surgery in the Management of Stage 3A Lung Cancer Zane Hammoud, M.D. Chief, General Thoracic Surgery Henry Ford Hospital No Disclosures Stage 3A Stage 3A Stage 3A: Issues At any stage, lung
More informationIs the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
More informationIs consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small cell lung cancer?
Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small cell lung cancer? ~A pooled analysis of the literature~ Satomi Yamamoto 1, Kazuyuki
More informationChemo-radiotherapy in non-small cell lung cancer. HARMESH R NAIK, MD. September 25, 2002
Chemo-radiotherapy in non-small cell lung cancer HARMESH R NAIK, MD. September 25, 2002 Epidemiology Estimated 170000 new cases Estimated 157,000 deaths Second commonest cancer diagnosis in men and women
More informationCombining chemotherapy and radiotherapy of the chest
How to combine chemotherapy, targeted agents and radiotherapy in locally advanced NSCLC? Dirk De Ruysscher, MD, PhD Radiation Oncologist Professor of Radiation Oncology Leuven Cancer Institute Department
More informationENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias. Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA
ENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA Formigal, 28 de Junio de 2018 CÓMO DEFINÍAMOS EL ESTADIO
More informationStage III NSCLC: Overview
Locally Advanced NSCLC: New Concepts in Combined Modality Therapy NSCLC: Stage Distribution Randeep Sangha, MD Visiting Assistant Professor UC Davis Cancer Center Sacramento, CA Stage III NSCLC: Overview
More informationAdjuvant radiotherapy for completely resected early stage NSCLC
Adjuvant radiotherapy for completely resected early stage NSCLC ESMO Preceptorship on lung Cancer Manchester March 2018 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique
More informationRTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
More informationStage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99
Stage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99 Introduction 1/3 of the total lung cancer cases few patients are cured with single modality
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationTreatment of Stage I-III SCLC
Treatment of Stage I-III SCLC Prof C Faivre-Finn Manchester Lung Cancer Group Manchester Radiation Related Research Group ESMO-The Christie Preceptorship programme on Lung Cancer 3 rd March 2017 @finn_corinne
More informationAdjuvant Radiotherapy for completely resected NSCLC
Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local
More informationInvolved field. Gy/30fr RTOG0617
.1 III 1980 60 Gy 10 2000 18 10 Involved field radiotherapy (IFRT) 2007 74 Gy/37 /7 60 Gy/30 /6 74 Gy 60 Gy ( 20.3 28.7 p=0.004) 1) 60 Gy/30fr 2 1) 2) 3) 1) 2) IMRT adaptive 2) hypofraction biomarker 3)
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationLung cancer update 2007
Lung cancer update 2007 HARMESH R NAIK, MD. January 24, 2007 Epidemiology (world) Estimated 1.35 million new cases in world in 2002 Estimated 1.179 million deaths in world in 2002 Common cancer diagnosis
More informationUpdate on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationCombined Chemotherapy and Radiation Therapy for Locally Advanced NSCLC
Combined Chemotherapy and Radiation Therapy for Locally Advanced NSCLC George R. Blumenschein, Jr., MD Associate Professor of Medicine Department of Thoracic/Head & Neck Medical Oncology The University
More informationTratamiento Multidisciplinar del CNMP Localmente Avanzado. Luis Paz-Ares
Tratamiento Multidisciplinar del CNMP Localmente Avanzado Luis Paz-Ares Indice Definición & Estadios Estadio IIIA N2 Estadio IIIB (y N2 irresecables) Conclusiones Indice Definición & Estadios Estadio IIIA
More informationAllan Price NHS Lothian, Edinburgh, UK
Allan Price NHS Lothian, Edinburgh, UK Radiotherapy Dose Volume Timing Technique PCI Surgery Systemic agents 1 Study Dose Time Induction CT Ann Arbor 65.1-75.6 Gy Duke 73.6-80 Gy RTOG 77.4 Gy 74 Gy 6.5-7.5
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationTreatment of LS (Stage I-III) SCLC
Treatment of LS (Stage I-III) SCLC Prof C Faivre-Finn Manchester Lung Cancer Group Manchester Radiation Related Research Group ESMO-The Christie Preceptorship programme on Lung Cancer 9 th March 2018 @finn_corinne
More informationSmall Cell Lung Cancer What we have now?
Small Cell Lung Cancer What we have now? Chunxue Bai, M.D., Ph.D. Chair, Chinese Alliance against Lung Cancer Shanghai Respiratory Research Institute Department of Pulmonary Medicine Zhongshan Hospital,
More informationWhere are we with radiotherapy for biliary tract cancers?
Where are we with radiotherapy for biliary tract cancers? Professor Maria A. Hawkins Associate Professor in Clinical Oncology MRC Group Leader/Honorary Consultant Clinical Oncologist CRUK MRC Oxford Institute
More informationLung cancer in the elderly. D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium
Lung cancer in the elderly D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Incidence and mortality of all cancers and lung cancer in relation to age and gender (US) 120,000
More informationThe Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology
The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology (specifically, lung cancer) 2/10/18 Jeffrey Kittel, MD Radiation Oncology, Aurora St. Luke s Medical Center Outline The history
More informationRole of Prophylactic Cranial Irradiation in Small Cell Lung Cancer
Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer Kazi S. Manir MD,DNB,ECMO,PDCR Clinical Tutor Department of Radiotherapy R. G. Kar Medical College and Hospital, Kolkata SCLC 15% of lung
More informationEstado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico
Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico Enriqueta Felip Vall d Hebron University Hospital Barcelona, Spain Stage I-II
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
More informationRadiation Therapy in SCLC. What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department
Radiation Therapy in SCLC What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department Background Overview Small Cell Lung cancer constitute about 15 % of all newly
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationLocally advanced head and neck cancer
Locally advanced head and neck cancer Radiation Oncology Perspective Petek Erpolat, MD Gazi University, Turkey Definition and Management of LAHNC Stage III or IV cancers generally include larger primary
More informationTHERAPY OF SMALL-CELL LUNG CANCER Peter Berzinec Specialised Hospital of St Zoerardus Zobor Teaching Base of the Slovak Medical University Nitra,
THERAPY OF SMALL-CELL LUNG CANCER Peter Berzinec Specialised Hospital of St Zoerardus Zobor Teaching Base of the Slovak Medical University Nitra, Slovakia Lancet. 1966;2(7471):979-86. First standard treatment:
More informationASTRO Andrew J. Hope, M.D.
IGRT for lung cancer; does XRT dose escalation improve outcome? Jeffrey Bradley, M.D. Associate Professor Department of Radiation Oncology Washington University and The Alvin J. Siteman Comprehensive Cancer
More informationUPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS
UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS Antonio M. Omuro Department of Neurology Memorial Sloan-Kettering Cancer Center II International Neuro-Oncology Congress Sao Paulo, 08/17/12 CHALLENGES IN
More informationPlace de la radiothérapie dans les CBPC métastatiques
Place de la radiothérapie dans les CBPC métastatiques Cecile Le Péchoux, 12 ème Biennale Monégasque de Cancérologie, 2016 IOT Institut d Oncologie Thoracique CBPC metastatique Rapid doubling time, early
More informationThe population of patients with stage III non
GREGORY M.M. VIDETIC, MD, CM, FRCPC Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH Locally advanced non small cell lung cancer: What is the optimal concurrent
More informationCasi clinici di integrazione multiprofessionale: NSCLC stadio III. Biagio Ricciuti. Scuola di Specializzazione in Oncologia Medica
Casi clinici di integrazione multiprofessionale: NSCLC stadio III Scuola di Specializzazione in Oncologia Medica Università degli Studi di Perugia Outline Standard treatment Open questions Clinical cases
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationCombined modality treatment for NSCLC with N2 disease
Combined modality treatment for NSCLC with N2 disease Gerry Hanna Senior Lecturer and Consultant in Clinical Oncology Centre for Cancer Research and Cell Biology @gerryhanna E: g.hanna@qub.ac.uk Talk Outline
More informationMinesh Mehta, Northwestern University. Chicago, IL
* Minesh Mehta, Northwestern University Chicago, IL Consultant: Adnexus, Bayer, Merck, Tomotherapy Stock Options: Colby, Pharmacyclics, Procertus, Stemina, Tomotherapy Board of Directors: Pharmacyclics
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationTreatment results of proton beam therapy with chemo-radiotherapy for stage I-III esophageal cancer
Treatment results of proton beam therapy with chemo-radiotherapy for stage I-III esophageal cancer Nobukazu Fuwa 1, Akinori Takada 2 and Takahiro Kato 3 1;Departments of Radiology, Hyogo Ion Beam Medical
More informationNRG Oncology Lung Cancer Portfolio 2016
NRG Oncology Lung Cancer Portfolio 2016 Roy Decker, MD PhD Yale Cancer Center Walter J Curran, Jr, MD Winship Cancer Institute of Emory University NRG Oncology Lung Cancer Selected Discussion Stage III
More informationDebate: Whole pelvic RT for high risk prostate cancer??
Debate: Whole pelvic RT for high risk prostate cancer?? WPRT well, at least it ll get the job done.or will it? Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Using T-stage,
More informationCancer Biology 2016;6(1)
Weekly Docetaxel and Cisplatin with Concomitant Radiotherapy in Addition to Consolidation Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer Hanan G. Mostafa and Mohamed-Alaaeldeen H. Mohamed
More informationMultidisciplinary interactive session (MIS) pn2: The optimal treatment in Wilfried Ernst Erich Eberhardt
Multidisciplinary interactive session (MIS) pn2: The optimal treatment in 2012 Wilfried Ernst Erich Eberhardt Department of Medicine (Cancer Res.), University Hospital Essen, West German Cancer Centre,
More informationCurrent Approaches for Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Current Approaches for Limited Small Cell Lung Cancer Laurie Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Can we improve or personalize treatment? Limited Histology/molecular
More informationConcurrent and sequential chemoradiotherapy. P. Van Houtte Department of Radiation Oncology Institut Jules Bordet
Concurrent and sequential chemoradiotherapy and radiotherapy for NSCLC P. Van Houtte Department of Radiation Oncology Institut Jules Bordet RADIOTHERAPY & CHEMOTHERAPY A very old concept «Benzene could
More informationRadiotherapy in NSCLC: What are the ESMO Guidelines?
- The role of radiation in early stage - RT/CT for unresectable NSCLC - Brain metastasis - Oligometastatic disease Radiotherapy in NSCLC: What are the ESMO Guidelines? Jean-Yves DOUILLARD MD PhD Chief
More information肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 Outline Current status of radiation oncology in lung cancer Focused on stage III non-small cell lung cancer Radiation
More informationCooperative Group Update - Japan; JCOG & WJOG -
Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine, Yokohama City University Chief, Division of Thoracic Surgery, Respiratory Disease Center
More informationESMO Preceptorship Programme NSCLC Singapore 15 November 2017
ESMO Preceptorship Programme NSCLC Singapore 15 November 2017 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo-adjuvant chemotherapy? Pr Jaafar BENNOUNA
More information3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationreceive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Management of Brain Metastases Dr. Luis Souhami Professor Department of Radiation Oncology University,
More informationElderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy fortune favours the bold
Editorial Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy fortune favours the bold Surein Arulananda 1,2,3, Paul Mitchell 1,3,4 1 Cancer Immuno-Biology Laboratory,
More informationDebate on stage III NSCLC: The role of systemic therapy
1 Debate on stage III NSCLC: The role of systemic therapy Rolf Stahel University Hospital of Zürich Bucharest, 16.6..2015 2 Stage III disease: The problem of heterogeneity, the risk of distant metastases
More information17th ESO ESMO Masterclass in Clinical Oncology
NSCLC Radiotherapy Prof Corinne Faivre-Finn Manchester Radiotherapy Related Research Group Manchester Lung Cancer Group The Christie, Manchester, UK 17 th ESO-ESMO Masterclass 25 th March 2018 Early stage
More informationStato dell arte del. Antonio ROSSI, MD. Division of Medical Oncology, S.G. MOSCATI HOSPITAL, AVELLINO - ITALY
Stato dell arte del trattamento del microcitoma Antonio ROSSI, MD Division of Medical Oncology, S.G. MOSCATI HOSPITAL, AVELLINO - ITALY Truly has become small. Last session/day in all meetings One chemo
More informationGastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
More informationCécile Le Péchoux Department of Radiation Oncology, Institut Gustave Roussy, Villejuif France Amsterdam 2010
Prophylactic Cranial Irradiation in Lung Cancer Cécile Le Péchoux Department of Radiation Oncology, Institut Gustave Roussy, Villejuif France Amsterdam 2010 Prophylactic cranial irradiation PCI was introduced
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Prague July 2016 State of the art: Standard of care for anal squamous cancer Rob Glynne-Jones Mount Vernon Cancer Centre Aim to discuss Background The trials
More informationAdjuvant Therapy in NSCLC. Dr.ssa Chiara Bennati Oncologia Medica S. Maria della Misericordia Perugia
Adjuvant Therapy in NSCLC Dr.ssa Chiara Bennati Oncologia Medica S. Maria della Misericordia Perugia Agenda What do we expect today from new adjuvant chemotherapy Which data do we have with targeted agents
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationEmerging Role of Immunotherapy in Head and Neck Cancer
Emerging Role of Immunotherapy in Head and Neck Cancer Jared Weiss, MD Associate Professor of Medicine and Section Chief of Thoracic and Head/Neck Oncology UNC Lineberger Comprehensive Cancer Center Copyright
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More information11/21/2009. Early Stage. Stage III. From Mountain: Chest, 1997
Combined odality egimens in Locally dvanced SCLC: Current Status and Future irections Primo. Lara, Jr, Professor of edicine University of California avis Cancer Center arly Stage Stage Five-Year Survival
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationRuolo emergente dell immunoterapia nello stadio III. Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy)
Ruolo emergente dell immunoterapia nello stadio III Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy) Disclosures Advisory Boards / Honoraria / Speakers fee / Consultant for: MSD,
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationClinical Activity Lung Cancer. Andrea Camerini Ospedale Versilia
Clinical Activity Lung Cancer Andrea Camerini Ospedale Versilia The three main objectives in advanced NSCLC 1. In advanced/metastatic cancer, palliation is often the primary treatment goal 2. Potential
More informationVATS after induction therapy: Effective and Beneficial Tips on Strategy
VATS after induction therapy: Effective and Beneficial Tips on Strategy AATS Focus on Thoracic Surgery Mastering Surgical Innovation Las Vegas Nevada Oct. 27-28 2017 Scott J. Swanson, M.D. Professor of
More informationCritical Clinical Updates
Critical Clinical Updates ASTRO Spring Refresher Course JW Marriott Hotel Ramesh Rengan MD PhD Department of Radiation Oncology Friday March 22, 2013 Learning Objectives At the conclusion of this activity,
More informationState of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy?
ESMO Preceptorship Programme NSCLC Singapore 13 14 dec 2016 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy? Pr Jaafar BENNOUNA
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationLung Cancer Radiotherapy
Lung Cancer Radiotherapy Indications, Outcomes, and Impact on Survivorship Care Malcolm Mattes, MD Assistant Professor WVU Department of Radiation Oncology When people think about radiation, they think
More informationRadiotherapy for rectal cancer. Karin Haustermans Department of Radiation Oncology
Radiotherapy for rectal cancer Karin Haustermans Department of Radiation Oncology O U T L I N E RT with TME surgery? Neoadjuvant or adjuvant RT? 5 x 5 Gy or long-course CRT? RT with new drugs? Selection
More informationNCCTG Status Report for Study N September 2007
Phase I/II Study of Concurrent Chemotherapy and Escalating Doses 3-D Conformal Radiotherapy (RT) Followed by Three Cycles of Chemotherapy for Unresectable Non-Small Cell Lung Cancer (NSCLC) Using a New
More information